SCG Cell Therapy

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
SCG Cell Therapy, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about SCG Cell Therapy please access Flcube.com

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about SCG Cell Therapy, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about SCG Cell Therapy please access Flcube.com

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status
CompanyDrug

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to SYN818, the company's proprietary Polθ (DNA polymerase theta) inhibitor, in combination with…

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

Hisun Animal Health Receives MARA Approval for Telmisartan Oral Solution for Cats – Expanding Pet Pharmaceutical Portfolio in Chronic Kidney Disease Treatment

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

GDK Biotechnology Receives NMPA Approval for Trivalent Influenza Split Vaccine – Faces Delisting Risk Warning Amid Seasonal Timing Constraints and Intensifying Competition

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study
CompanyDrug

SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study

SCG Cell Therapy's SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial
CompanyDrug

SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024
CompanyDrug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

CompanyDrug

SCG Cell Therapy Receives FDA Approval for HPV-Targeted SCG142 Clinical Trial

CompanyDrug

SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China

Company

SCG Cell Therapy Launches Global Manufacturing and R&D Center in Singapore with Automated System